Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27159559 | 1.00 | CTSS (0.52) | CTSSCTSKPPARAPPARGALDH1A1 | |
| SCHEMBL12195416 | 1.00 | CTSS (0.52) | CTSSCTSKPPARAPPARGALDH1A1 | |
| SCHEMBL16174090 | 0.89 | CTSK (0.50) | CTSSCTSKPPARAPPARGALDH1A1 | |
| SCHEMBL16171653 | 0.89 | CTSK (0.50) | CTSSCTSKPPARAPPARGALDH1A1 | |
| SCHEMBL191987 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL191986 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL843924 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL264362 | 0.87 | CTSK (0.66) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL116386 | 0.87 | CTSK (0.66) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL525862 | 0.87 | CTSK (0.66) | CTSSCTSKPPARAPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955391-A | Substituted N- (2-oxo ethyl) benzamide derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-11-15 | — | — | CN | disclosed |
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-2813502-B1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPÉ FARM S P A (IT) | 2017-01-04 | — | — | EP | disclosed |
| US-9409876-B2 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| EP-2643295-B1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2016-04-13 | — | — | EP | disclosed |
| EP-2643295-B1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2016-04-13 | — | — | EP | disclosed |
| CN-103221390-B | Glycine derivatives and pharmaceutical compositions thereof | CHIESI FARMA SPA | 2015-06-03 | — | — | CN | disclosed |
| US-20140371274-A1 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| EP-2813502-A1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe' S.p.A. (IT) | 2014-12-17 | — | — | EP | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| EP-2643295-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | Chiesi Farmaceutici S.p.A. (IT) | 2013-10-02 | — | — | EP | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | CTSS 4443/4885CTSK 3906/4885PPARA 1912/4885 |
| US-20140371274-A1 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BDKRB1, BDKRB2, EDNRB | CTSS 1957/4885CTSK 1184/4885PPARA 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.